EGFR and ovarian cancer: Furthermore, some studies have shown that UCA1 was related to drug resistance in some malignancies, including ovarian cancer, bladder cancer and EGFR-mutant NSCLC, suggesting that UCA1 could be applied as a biomarker for monitoring the efficacy of chemotherapy [29, 35–36].